According to Orthofix Medical 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.90515. At the end of 2024 the company had a P/E ratio of -5.31.
Year | P/E ratio | Change |
---|---|---|
2024 | -5.31 | |
2022 | -20.9 | 30.72% |
2021 | -16.0 | |
2019 | -30.6 | -142.53% |
2018 | 71.9 | -55.31% |
2017 | 161 | -24.41% |
2016 | 213 | -181.42% |
2015 | -261 | 221.75% |
2014 | -81.2 | 476.75% |
2013 | -14.1 | -196.34% |
2012 | 14.6 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() NuVasive NUVA | 73.6 | -2,633.81% | ๐บ๐ธ USA |
![]() Smith & Nephew
SNN | 26.7 | -1,018.52% | ๐ฌ๐ง UK |
![]() Stryker Corporation SYK | 52.4 | -1,903.85% | ๐บ๐ธ USA |
![]() Globus Medical GMED | 41.5 | -1,527.10% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.